| __timestamp | Neurocrine Biosciences, Inc. | Zoetis Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 17986000 | 1643000000 |
| Thursday, January 1, 2015 | 32480000 | 1532000000 |
| Friday, January 1, 2016 | 68081000 | 1364000000 |
| Sunday, January 1, 2017 | 169906000 | 1334000000 |
| Monday, January 1, 2018 | 248932000 | 1484000000 |
| Tuesday, January 1, 2019 | 354100000 | 1638000000 |
| Wednesday, January 1, 2020 | 433300000 | 1726000000 |
| Friday, January 1, 2021 | 583300000 | 2001000000 |
| Saturday, January 1, 2022 | 752700000 | 2009000000 |
| Sunday, January 1, 2023 | 887600000 | 2151000000 |
| Monday, January 1, 2024 | 1007200000 | 2318000000 |
Unleashing the power of data
In the competitive landscape of biopharmaceuticals, understanding operational efficiency is crucial. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Zoetis Inc. and Neurocrine Biosciences, Inc. from 2014 to 2023. Over this period, Zoetis Inc. consistently maintained higher SG&A expenses, peaking at approximately $2.15 billion in 2023, reflecting its expansive market reach and robust operational framework. In contrast, Neurocrine Biosciences, Inc. exhibited a remarkable growth trajectory, with SG&A expenses surging from $18 million in 2014 to nearly $888 million in 2023, marking an impressive 48-fold increase. This growth underscores Neurocrine's aggressive expansion strategy and increasing market penetration. The data highlights the distinct strategic approaches of these companies, offering valuable insights into their operational priorities and market positioning.
Novo Nordisk A/S and Zoetis Inc.: SG&A Spending Patterns Compared
Johnson & Johnson vs Zoetis Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Pfizer Inc. or Neurocrine Biosciences, Inc.
Selling, General, and Administrative Costs: Zoetis Inc. vs Protagonist Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Zoetis Inc. and Galapagos NV
Breaking Down SG&A Expenses: Zoetis Inc. vs BioCryst Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Teva Pharmaceutical Industries Limited and Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. or Intra-Cellular Therapies, Inc.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Neurocrine Biosciences, Inc. vs Grifols, S.A.
Neurocrine Biosciences, Inc. and PTC Therapeutics, Inc.: SG&A Spending Patterns Compared
Neurocrine Biosciences, Inc. or Perrigo Company plc: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Neurocrine Biosciences, Inc. vs MannKind Corporation